Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Orchard Therapeutics

Orchard Therapeutics
2015 FOUNDED
PUBLIC STATUS
101-200 EMPLOYEES
ORTX STOCK SYMBOL
1 INVESTMENTS
$11.53 SHARE PRICE (As of Tuesday Closing)
Description

Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fully-integrated biopharmaceutical company. The company is engaged in transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. It operates in three geographic regions: the United Kingdom, European Union, and the United States. Orchard Rx is focusing on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, used for the treatment of ADA-SCID five lentiviral product candidates.

Formerly Known As
Newincco 1387
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 108 Cannon Street
  • London EC4N 6EU
  • England, United Kingdom

+44 020 0000 0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Orchard Therapeutics’s full profile, request a free trial.

Orchard Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$8.65 - $21.64 $1.11B $11.36 $5.85 200K 96.2M

Orchard Therapeutics Financials Summary

In Thousands,
USD
TTM
30-Jun-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 910,092 1,273,300
Revenue 2,076 0 0
EBITDA (137,794) (228,326) (39,389) (19,059)
Net Income (140,220) (230,495) (39,744) (19,085)
Total Assets 458,117 366,042 97,294 4,283
Total Debt 24,501
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Orchard Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Orchard Therapeutics‘s full profile, request access.

Request full access to PitchBook

Orchard Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Orchard Therapeutics‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Orchard Therapeutics Competitors (72)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ultragenyx Pharmaceutical Formerly VC-backed Novato, CA 000 00000 00000000 00000
00000000 Formerly VC-backed Paris, France 00 000.00 00000000 000.00
0000000 000000 Formerly VC-backed Lyon, France 000 00000 000000000 00000
0000000 0000000000 Venture Capital-Backed La Jolla, CA 00000 000000000000 00000
000000 00000000000 Failed Transaction (M&A) Cambridge, MA 000 00000 000000&0
To view this company’s complete list of competitors, request access »

Orchard Therapeutics Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000000000 (0 12-Apr-2018 000000000 00000 00 Other Business Products and Services 0000 0000000
To view this company’s complete investment and acquisition history, request access »

Orchard Therapeutics Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Orchard Therapeutics‘s full profile, request access.

Request full access to PitchBook

Orchard Therapeutics Executive Team (9)

Name Title Board
Seat
Contact
Info
Mark Rothera Chief Executive Officer & Board Member
Frank Thomas Chief Financial Officer & Executive
Bobby Gaspar Chief Scientific Officer & Board Member
Nicolas Koebel Chief of Staff & Head of Program Management
Stewart Craig Ph.D Chief Manufacturing Officer

1 Former Executive

You’re viewing 5 of 9 executives. Get the full list »

Orchard Therapeutics Board Members (16)

Name Representing Role Since Contact
Info
Alexander Pasteur Ph.D F-Prime Capital Partners Board Member 000 0000
Alicia Secor Self Board Member 000 0000
Bobby Gaspar Orchard Therapeutics Chief Scientific Officer & Board Member 000 0000
Charles Rowland Jr. Self Board Member 000 0000
Gaspar Hubert Orchard Therapeutics Board Member 000 0000

2 Former Board Members

You’re viewing 5 of 16 board members. Get the full list »